Cardiol Therapeutics Closes $13.5M Public Offering
Ticker: CRDL · Form: 6-K · Filed: Oct 10, 2024 · CIK: 1702123
| Field | Detail |
|---|---|
| Company | Cardiol Therapeutics INC. (CRDL) |
| Form Type | 6-K |
| Filed Date | Oct 10, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $13.5Million |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, public-offering, biotech
TL;DR
Cardiol Therapeutics just closed a $13.5M public offering, boosting their war chest.
AI Summary
Cardiol Therapeutics Inc. announced the closing of a public offering on October 10, 2024, raising US$13.5 million. The company, headquartered in Oakville, Ontario, Canada, is involved in the biological products sector.
Why It Matters
This capital infusion provides Cardiol Therapeutics with additional resources to advance its business objectives, potentially impacting its research and development pipeline.
Risk Assessment
Risk Level: medium — The company operates in the volatile biotechnology sector, and the success of its public offering depends on market conditions and investor confidence.
Key Numbers
- US$13.5M — Capital Raised (Funds secured from the public offering to support company operations and growth.)
Key Players & Entities
- Cardiol Therapeutics Inc. (company) — Registrant
- US$13.5 million (dollar_amount) — Amount raised in public offering
- October 10, 2024 (date) — Closing date of public offering
- Chris Waddick (person) — Chief Financial Officer
FAQ
What is the primary business of Cardiol Therapeutics Inc.?
Cardiol Therapeutics Inc. is involved in the biological products sector, specifically focusing on biological products (no diagnostic substances).
When did Cardiol Therapeutics Inc. announce the closing of its public offering?
The news release announcing the closing of the public offering was dated October 10, 2024.
What was the total amount raised in the public offering?
The company announced the closing of a public offering that raised US$13.5 million.
Who signed the Form 6-K report on behalf of Cardiol Therapeutics Inc.?
The report was signed by Chris Waddick, Chief Financial Officer, on behalf of Cardiol Therapeutics Inc.
Where is Cardiol Therapeutics Inc. headquartered?
Cardiol Therapeutics Inc. is headquartered at 602-2265 Upper Middle Road East, Oakville, Ontario, L6H 0G5, Canada.
Filing Stats: 164 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-10-10 15:14:44
Key Financial Figures
- $13.5Million — iol Therapeutics Announces Closing of US$13.5Million Public Offering of Common Shares
Filing Documents
- tm2424074d4_6k.htm (6-K) — 10KB
- tm2424074d4_ex99-1.htm (EX-99.1) — 10KB
- tm2424074d4_ex99-1img01.jpg (GRAPHIC) — 6KB
- tm2424074d4_ex99-1img02.jpg (GRAPHIC) — 3KB
- 0001104659-24-107687.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CARDIOL THERAPEUTICS INC. (Registrant) Date: October 10, 2024 By: /s/ Chris Waddick Name: Chris Waddick Title: Chief Financial Officer Form 6-K Exhibit Index Exhibit Number Document Description 99.1 News Release dated October 10, 2024 – Cardiol Therapeutics Announces Closing of US$13.5Million Public Offering of Common Shares